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Coronary lesion location
Left main artery 1
Left anterior descending 12
Right coronary artery 7
Left circumflex artery 4
Number of patients 13
Angiographic success rate 100%
MI/Cardiac death in-hospital, 1 yr 0
Stent diameter (mm) 3 0.6
Stent length (mm) 15 4.9
Number of lesions treated 24
Coronary lesion location
Left main artery 1
Left anterior descending 12
Right coronary artery 7
Number of stents 26
Angiographic follow-up 100%
Length of follow-up 325 128
Binary restenosis 7.4%
Target vessel revascularization 1/24 (4.1%)
Target lesion revascularization 1/26 (3.8%)
Conclusions: EES is associated with a very low incidence of instent stenosis and target
lesion revascularization in patients with TCAD. Further studies are needed to determine
whether PCI with EES could alter the long term outcome of patients with TCAD.
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Background: Nobori stent (Terumo Co., Tokyo Japan), is the new concept Drug Eluting
Stent which has unique bioabsorbable polymer (Poly-Lactic Acid) and the anti-
proliferative agent Biolimus A9. We investigated the safety and the efficacy of Nobori
stent comparing to Cypher stent in Japanese population by a single blinded 3:2
randomized trial and met the primary endpoint, non inferiority in TVF. This is the first
report of three year clinical follow up data of Nobori Biolimus Eluting stent compared to
Cypher Sirolimus Eluting stent in Japanese population.
Methods: This is the first multicenter single-blinded, 3:2 randomized clinical trial
comparing Nobori and Cypher in 335 patients (Nobori 198 : Cypher 137) in Japan.
Patients with single de novo up to two native coronary lesions were treated. The primary
endpoint was TVF (cardiac death, MI and TVR) rate at 9 months; late loss (LL) and
restenosis rate (RR) at 8 months were major secondary angiographic endpoints, while
MACE and stent thrombosis were major secondary safety endpoints. Duration of dual
antiplatelet therapy (DAPT) was also recorded for all patients.
Results: No significant difference between both patient backgrounds was found. TLR
free rate of Nobori was 98.8% at 2years and 98.3% at 3years. (Cypher 96.0% and 95.2%).
MACE free rate of Nobori was 94.1% at 2years and 92.9% at 3years. (Cypher 93.7% and
92.0%). TVF free rate of Nobori was 92.1% at 2years and 90.9% at 3years. (Cypher
93.7% and 91.1%). No definite or probable stent thrombosis according to ARC definition
were found in both groups.
Conclusions: In this first randomized clinical trial of Nobori and Cypher stent in
Japanese population, Nobori stent was found non-inferior to Cypher in TVF, the primary
endpoint. TLR free rate at 3 years of Nobori tended to be higher than that of Cypher and
the differences in TLR free rate between Nobori and Cypher at 2 years and 3years were
increased (no statistical significance). MACE and TVF free rate of both stents at three
years were comparable. Further long term follow-up up to 5years may suggest longer term
safety of Nobori Stent.
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Background: There are few studies comparing the long-term clinical outcomes of
patients (pts) with peri-procedural myocardial infarction (P-MI) with those without P-MI
following percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) in
real world clinical practice.
Methods: A total of 1119 pts underwent PCI with DESs between 2004 and 2010 were
enrolled (control group, n1006 pts and P-MI group, n113 pts). P-MI was defined as
major CK-MB elevation (3X the upper limit of normal [ULN]) after PCI.
Results: There were no significant differences between the two groups except P-MI
group was more elderly, had more female, longer procedure time, higher number of target
vessel and stents. At 6 month routine follow-up angiography, there was no significant
difference in mean diameter stenosis %, incidence of binary restenosis and late loss
between the two groups. Among the major in-hospital outcomes, cardiac death was higher
in P-MI group. At 2-year (follow-up, 89.1%), and the cumulative incidence of total death,
cardiac death and total major adverse cardiac events (MACEs) were higher in P-MI group,
where as repeat PCI including target lesion revascularization (TLR) and target vessel
revascularization (TVR). However, when in-hospital mortality was excluded, the major
clinical outcomes were not different between the two groups up to 2 years (table).
Conclusions: P-MI was mainly associated with in-hospital cardiac death following PCI
with DES in real world clinical practice. However, P-MI doesn’t seem to be an
independent predictor for adverse clinical outcomes for long-term period.
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Background: Previous studies were performed to investigate whether a strategy of direct
stent implantation without pre-dilatation is associated with a reduced incidence of
restenosis, compared to conventional stenting with pre-dilatation. However, none of these
studies were performed in the drug-eluting stent era. Therefore the STRESSED (direct
Stenting To Reduce REStenosis in Stent Era with Drug elution) study was designed and
carried out.
Methods: A total of 600 patients with stable or unstable angina pectoris or a recent (30
days) myocardial infarction were randomized to direct stenting, stenting after pre-
dilatation or a provisional stenting strategy. Primary endpoint was the mean minimal
lumen diameter (MLD) at 9 months follow-up angiography. Secondary endpoints were
the clinical procedural success defined as angiographic success without major adverse
cardiac events (MACE) at 9 months and two years follow-up.
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